chemotherapy-All India Institute of Medical Sciences-hepatocellular carcinoma

chemotherapy-All India Institute of Medical Sciences-hepatocellular carcinoma refers to a clinical trial protocol (NCT02240771) developed by the All India Institute of Medical Sciences (AIIMS) to evaluate palliative treatment strategies for patients with unresectable hepatocellular carcinoma (HCC) and portal vein invasion. The protocol compares two distinct therapeutic approaches: Transarterial Chemotherapy (TAC), which involves the localized intra-arterial injection of doxorubicin and cisplatin directly into the tumor's feeding vessels without subsequent embolization, and a systemic oral chemotherapy regimen consisting of thalidomide and capecitabine. This study specifically targets patients at Barcelona Clinic Liver Cancer (BCLC) stage C, for whom standard curative options or transarterial chemoembolization (TACE) are often unsuitable due to the risk of liver failure associated with portal vein involvement. The trial aims to determine which modality provides superior outcomes in this advanced patient population.

Other names

TAC vs Oral Thalidomide and CapecitabineTransarterial chemotherapy vs Oral chemotherapy AIIMS HCC trialTAC vs Oral chemotherapy in unresectable HCC